Coherus reports confirmed response rate for tagmokitug combination in esophageal cancer
Coherus reported a confirmed response rate for its tagmokitug combination in esophageal cancer.
Related stories
Shanghai Composite Opens 1.3% Lower
M impact | EQUITY | Oct 30, 2026, 01:32 AM UTC
Raon Robotics Q3 Operating Profit Rises 259.3% to 4 Billion Won
Raon Robotics reported Q3 operating profit of 4 billion won, up 259.3% from a year earlier.
M impact | EQUITY | Oct 30, 2026, 01:28 AM UTC
Doctor Care Anywhere Reports Q3 2026 Revenue of £11.3M
M impact | EQUITY | Oct 30, 2026, 01:28 AM UTC
China 5G Communications Index Set to Open Down More Than 5%
M impact | EQUITY | Oct 30, 2026, 01:27 AM UTC
Daewoo E&C Signs Amended 274.89 Billion Won Housing Contract
Daewoo E&C signed an amended 274.89 billion won contract for Changwon housing redevelopment.
M impact | EQUITY | Oct 30, 2026, 01:27 AM UTC
Calmer Co International Posts Q1 FY27 Revenue of A$2.44 Million
M impact | EQUITY | Oct 30, 2026, 01:27 AM UTC